SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heightened volatility as market participants react to recent geopolitical rhetoric from former President Trump, particularly concerning potential tariffs and comments about Greenland, which has sparked significant uncertainty among international allies. Community sentiment reflects apprehension about these developments, fueling discussions around a potential "Sell America" trade and a noticeable shift toward safe-haven assets like gold and silver amid broader economic and geopolitical concerns.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending after reporting positive Phase 1 clinical trial data for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile, particularly in treatment-resistant patients. The news has ignited significant community discussion around a potential short squeeze and sustained bullish momentum, with many anticipating future partnerships or a buyout. This early success in a large therapeutic market is generating considerable interest in the stock's long-term potential.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing heightened volatility due to renewed global trade tensions, specifically concerning former President Trump's comments on Greenland and potential tariffs on European allies. The community is sharply divided, with bears anticipating a deeper market correction driven by geopolitical concerns and bond market stability, while bulls are aggressively buying dips, confident in a swift rebound and a potential policy reversal. This dynamic creates significant swings as participants debate the market's underlying strength amidst uncertainty.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following positive regulatory developments, as the FDA requested no new trials for its ANKTIVA cancer therapy's sBLA resubmission, signaling an accelerated path to market. The community is buzzing with optimism, anticipating substantial long-term growth driven by this key de-risking event and international market opportunities, while also discussing the potential for a significant short squeeze.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending due to significant market instability sparked by high-profile geopolitical rhetoric and broader financial concerns, including stress in Japan's bond market. The crypto community is intensely debating Bitcoin's status as a reliable hedge asset, noting substantial liquidations even as prominent institutions continue making large acquisitions. This dynamic creates a highly volatile environment and fuels ongoing discussion about its near-term trajectory.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a major talking point ahead of its earnings report, with community sentiment sharply divided on whether subscriber growth and ad-tier performance will spark a rally or a significant drop. The recent all-cash offer for Warner Bros. Discovery assets is a key discussion point, seen by some as a strategic play to secure the deal and by others as a potentially costly move impacting future debt. Traders are also noting the stock's oversold conditions, with some positioning for a rebound despite broader market uncertainties.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is a trending topic amidst a prolonged downtrend and consistent selling pressure, defying recent positive reports of strong iPhone sales and market share gains, particularly in China. The community remains sharply divided, with many expressing frustration over its 'oversold' status and speculating on market manipulation, while others view the pullback as a significant buying opportunity ahead of its upcoming earnings report and potential clarifications on its AI strategy, including its partnership with Google Gemini.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to reports of Zydus Lifesciences exploring a controlling stake or key asset acquisition, alongside strong preliminary revenue figures and a significant patent extension for IBSRELA and XPHOZAH until 2041. The community is buzzing about the game-changing patent extension, accelerating IBSRELA's path to $1 billion in annual revenue by 2029, and speculating on a potential buyout or bidding war, despite some historical skepticism around sustained gains. Analysts have responded with multiple price target upgrades, highlighting the company's strengthened long-term valuation and potential for sustained growth with two approved drugs.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following multiple analyst upgrades, renewed investor optimism from CES, and significant news of winning a U.S. SHIELD defense contract for advanced chip manufacturing. The community is actively debating the stock's ability to break through key resistance levels, with many believing the company is undervalued amidst the ongoing AI race and its strategic position in domestic chip production, despite some Wall Street caution ahead of upcoming earnings.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amid its announced record date for a new digital token initiative, which the community is discussing as a potential catalyst for a short squeeze. This development, coupled with ongoing geopolitical narratives and commentary surrounding its figurehead, fuels significant market speculation and contributes to its high volatility.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Scilex (NASDAQ:SCLX) Stock Price Down 3% - Time to Sell?

Scilex (NASDAQ:SCLX) Shares Down 3% - Time to Sell...

Scilex (NASDAQ:SCLX) Stock Price Down 1.3% - Time to Sell?

Scilex (NASDAQ:SCLX) Shares Down 1.3% - What's Next...

<ul class="summary-bullets"><li>The first tranche in September 2025 was $8 million in Bitcoin.</li><li>The second tranche of $141.93 million brings the total investment to $150 million.</li><li>Datavault said the funds will boost digital asset reserves, supercomputing, platform growth, and new revenue streams.</li></ul>Datavault AI (DVLT) announced on Wednesday that it has closed the second tranche of a strategic Bitcoin (BTC)-backed investment from Scilex (SCLX), securing capital to expand its digital asset reserves.In this deal, Scilex used 1,237.6 Bitcoin (BTC) to receive a pre-funded warrant that can be converted into roughly 264 million Datavault shares.&nbsp;In total, Scilex is expected to receive approximately 278.9 million Datavault shares, including 15 million in common stock from the first tranche of investment.The first tranche of the investment, completed in September 2025, was also made in Bitcoin and valued at about $8 million.&nbsp;With the $141.93 million second tranche, the combined investment totals approximately $150 million.&nbsp;Datavault said the investment will help it grow its digital asset reserves, expand supercomputing infrastructure, develop its platform, and create new revenue opportunities.&nbsp;<h2 class="st-heading-2">The Market Reaction</h2>Scilex Holding Company and Datavault partnered in September following Scilex’s $150 million investment. In addition to the capital infusion, Scilex secured a worldwide exclusive license reportedly valued at up to $10 million for Datavault’s AI and tokenization technology, focused on monetizing real-world assets and data, particularly in biotech and healthcare.<a href="https://stocktwits.com/symbol/SCLX">SCLX’s stock</a> dropped as much as 3.65% in pre-market trade despite strength in the broader market. On Stocktwits, it was among the top trending tickers. Data showed retail sentiment around the company rose to ‘extremely bullish’ from ‘bullish’ territory, accompanied by ‘high’ levels of chatter over the past day.&nbsp;<a href="https://stocktwits.com/symbol/DVLT">DVLT’s stock</a> edged 0.4% lower, with retail sentiment around the firm improving to ‘bullish’ from ‘neutral’ over the past day, with chatter at ‘high’ levels.<h2 class="st-heading-2">What Is Retail Thinking?</h2>One bullish user on Stocktwits said Scliex’s position in Datavault is now worth more than the original $150 million investment.&nbsp;<stembedurl>https://stocktwits.com/Sacsofcash/message/637487414</stembedurl>Another bullish trader anticipates ample runway ahead for the stock’s price to gain.<stembedurl>https://stocktwits.com/ToxicAvenger/message/637491996</stembedurl>SCLX’s stock has gained more than 30% this year, while DVLT’s stock has gained almost 10%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-xrp-ada-struggle-ahead-of-thanksgiving-analyst-warns-no-catalyst/cL53V2sREWP">Bitcoin, XRP, ADA Struggle Ahead Of Thanksgiving – Analyst Warns There’s No Clear Catalyst For Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of Bitcoin with stock market data. (Source: Andriy Onufriyenko/Getty Images)

Scilex Injects More Bitcoin Into Datavault AI, Unlocks 264M Share Warrant Issue

Retail sentiment on Stocktwits around both stocks rose over the past day, despite slight pre-market share price declines.

Equity

<ul class="summary-bullets"><li>Record shareholders of Scilex Holding Company will also be eligible for the meme coin airdrop.</li><li>Datavault AI described the decision as a gesture of appreciation for Scilex’s role as a stockholder, licensing partner, and co-sponsor of Dream Bowl XIV.</li><li>The board retains the right to alter the record date or revoke the airdrop before distribution based on solvency or surplus considerations.</li></ul>Datavault AI (DVLT) traded higher in pre-market hours on Monday after announcing that record shareholders as of today will qualify for its Dream Bowl 2026 meme coin airdrop set for January.<a href="https://stocktwits.com/symbol/DVLT/">DVLT’s stock</a> rose as much as 2.75% in pre-market trade. On Stocktwits, retail sentiment around the company dipped to ‘neutral’ from ‘bullish’ territory over the past day. To qualify for the distribution, holders must own Datavault AI shares as of the record date of November 25, 2025, the company said Friday.<h2 class="st-heading-2">Scilex Equity Holders Included in Airdrop Plan</h2>The company also said the airdrop will extend to record holders of Scilex Holding Company (SCLX) common stock. Datavault AI described the decision as a gesture of appreciation for Scilex’s role as a stockholder, licensing partner, and co-sponsor of Dream Bowl XIV, which is scheduled for January 11, 2026.<a href="https://stocktwits.com/symbol/SCLX">SCLX’s stock</a> rose as much as 18% in pre-market trade but later reversed, moving nearly 5% lower as the market open approached. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory, with chatter at ‘high’ levels.<h2 class="st-heading-2">Distribution Terms and Board Discretion</h2>Datavault AI said the Dream Bowl 2026 Meme Coins will be distributed to Data Vault wallets after the payment date, provided recipients elect to opt in, set up a digital wallet, and supply the required documentation.The company added that its Board of Directors may change the record date at any time before the payment date. The distribution remains subject to the Board’s approval and may be revoked, including in the event of a material change to the solvency or surplus analysis previously presented.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-holds-86000-crypto-market-back-above-3-trillion-xrp-doge-gain/cL5bex0REQP">Bitcoin Holds $86,000 With Crypto Market Back Above $3 Trillion – XRP, Doge Gain Ahead Of Grayscale’s New ETF Launches</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Datavault AI logo is seen displayed on a smartphone screen.

DVLT Shares Rise In Pre-Market On Upcoming Meme Coin Distribution For Record Shareholders

Record shareholders as of Monday will be eligible to receive the airdrop, scheduled for January.

Scilex (NASDAQ:SCLX) Posts Earnings Results, Misses Expectations By $21.76 EPS

Scilex (NASDAQ:SCLX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($22.17) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Scilex Holding Company (SCLX) on Thursday said that its majority-owned subsidiary, Semnur Pharmaceuticals, and Denali Capital Acquisition Corp (DECA) have entered into a purchase agreement with an investor for a $20 million private placement.The proceeds of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/10161/pdf">agreement</a> will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain. Lumbosacral radicular pain, often referred to as sciatica, is a pain that radiates along the sciatic nerve, which extends from the lower back down the leg.On Stocktwits, retail sentiment around Scilex remained within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels. <a href="https://stocktwits.com/symbol/SCLX">SCLX stock</a> is trading 0.5% lower in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:567/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_21_at_7_24_17_AM_png_36aea133ff.webp" alt="SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits" width="567" height="60"><figcaption>SCLX's Sentiment Meter and Message Volume as of 7:24 a.m. ET on Aug. 21, 2025 | Source: Stocktwits</figcaption></figure>Semnur and special purpose acquisition company (SPAC) Denali entered into a <a target="_blank" rel="noopener noreferrer nofollow" href="https://scilexholding.gcs-web.com/node/9226/pdf">plan of merger</a> on Aug. 30, 2024, for a proposed business combination, among Semnur, the SPAC, and the SPAC's unit Denali Merger Sub Inc. This provided for a pre-transaction equity value of Semnur at $2.5 billion.&nbsp;Under the deal, the combined company will be renamed Semnur Pharmaceuticals, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol “SMNR”. The combination is now expected to close in September 2025.An investor has agreed to purchase an aggregate of 1.25 million shares of common stock of the combined company following the consummation of the merger transaction, Scilex said. The purchase price for the placement is $16.00 per share, for an aggregate purchase price of $20 million.The closing of the financing is subject to customary conditions and is expected to occur immediately following the consummation of the business combination, Scilex said.The company also said that CEO Jaisim Shah resigned as Scilex CEO and will now serve as chief executive and President of Semnur. Henry Ji, who currently serves as Executive Chairman of Scilex, was appointed as Scilex’s new CEO and President and has assumed all of the duties formerly performed by Shah, the company said.SCLX stock is up by 18% this year and down by 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/two-players-quietly-took-over-bitcoin-mining-power-heres-why-it-matters/chsSu9WRdi5">Two Players Quietly Took Over Bitcoin’s Mining Power — Here’s Why It Matters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside

The proceeds of the agreement will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain.

Scilex Holding Co. (SCLX), a relatively under-the-radar player in the non-opioid pain management space, has unexpectedly captured the attention of retail investors. The company experienced a staggering 41.78% increase in retail followers on Stocktwits over the past month, despite a 21% decline in its share price.However, the initial bullish sentiment has waned, with Stocktwits sentiment flipping to bearish (36/100) and message volumes surging. This shift suggests growing investor skepticism amidst recent company developments.<figure class="image"><img style="aspect-ratio:1316/306;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SCLX_Sentiment_and_message_score_Aug_1_f79a43cdac.png" alt="SCLX Sentiment and message score Aug 1.png" width="1316" height="306"><figcaption>SCLX Sentiment and message score Aug 1</figcaption></figure>The surge in retail interest can be attributed to several factors. Primarily, the announcement of a potential $2 billion deal for its subsidiary, Semnur Pharmaceuticals, to go public through a SPAC merger with Denali Capital Acquisition Corp (DECA) has generated excitement. The proceeds from this deal are earmarked for the development of SP-102, a key drug candidate in late-stage trials.Additionally, Scilex had reported preliminary Q2 net sales above estimates, indicating revenue growth. However, a significant decline in cash and cash equivalents raised concerns.The company also entered into a collaboration agreement with ACEA for the potential expansion of its ZTlido treatment, used to help relieve nerve pain after shingles, in the Greater China region.While July saw continued sales growth for ZTlido, the pace of growth slowed compared to the previous month. This, coupled with the overall bearish sentiment and declining cash reserves, seems to have tempered initial enthusiasm.With Q2 earnings report scheduled for August 9th after market hours, investors will be closely watching for further clarity on the company's financial health and the progress of its key initiatives.Photo via Vecteezy

Small-Cap Scilex Drew Biggest Jump In Retail Following For July: What Drove It?

Retail investors flocked to Scilex, drawn by news about a lucrative SPAC deal for its unit, declining cash reserves and slowing sales growth.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

SCLX
Scilex Holding Company

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SCLX News

SCLXScilex Holding Company